Cencora, Inc. (COR) Stock: Price, Forecast & Analyst Target
Cencora, Inc. (COR) — MoonshotScore 86/100 (Exceptional band), calculated Nov 18, 2026. Price $341.25 (-2.03%), as of the Nov 19, 2026 trading session; market cap $65.1B. Expected results Feb 3, 2027.
Educational signal · not a buy or sell recommendation · How to read this
Cencora, Inc. · COR · NYSE · Healthcare · Medical - Distribution
Research dated 2026-09-12: Cencora moves medicines and related healthcare products from manufacturers to pharmacies, hospitals, clinics and other care settings, while adding specialty logistics, commercialization support and animal-health distribution. The case rests on whether rising product throughput and service breadth can produce durable profit and cash generation despite exceptionally thin distribution margins and debt well above cash.
Price as of Nov 19, 2026
Key Statistics
MoonshotScore v2 · Cencora (COR)
ExceptionalWhy this rating? Method, drivers & history
Bands for the MoonshotScore: Exceptional 80-100 · Strong 65-79 · Fair 45-64 · Weak below 45.
- Business Quality — Is this a genuinely good business?
- Financial Safety — Could this blow up on me?
- Valuation — Am I paying a fair price?
- Growth Durability — Is the growth real and likely to last?
- Momentum — Is the market already moving on this?
High quality and elite growth, though the balance sheet is only decent; the market is already moving on it. Business Quality: Solid; Financial Safety: Okay; Valuation: Fair; Growth Durability: Compounding; Momentum: Surging.
- EPS beat 0 of the last 4 reports
- expected results Feb 3, 2027
- Altman Z 4.50 · Piotroski F 7
Helping: business quality, an attractive price, durable growth, positive momentum
What has the MoonshotScore done over time?
| Recorded | Score | Band |
|---|---|---|
| 86 | Exceptional | |
| 82 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional | |
| 86 | Exceptional |
Daily score refresh is delayed. This is the last recorded calculation.
Calculation uses the most recent completed US trading session. Live price changes do not update the score immediately.
Computed · How the MoonshotScore is computed →
Price & valuation
| Measure | Value | As of |
|---|---|---|
| Latest provided price | $341.25 | |
| Change on the day | -2.03% | |
| 52-week range | $244.82–$377.54 | |
| Market capitalisation | $65.1B | — |
| Price / earnings (trailing) | 19.49 | |
| Shares traded on the day | 895.8K | |
| Beta (volatility vs the S&P 500) | 0.58 |
Why Cencora scores 86
Share price, last 12 months -4.4%
$364.65 $348.71
What the price assumes
5.1% a year of free-cash-flow growth for ten years is what a $66.54B market value ( snapshot) asks for.
The price asks for less growth than the business has been producing. The question it leaves open is how long that pace lasts, not whether it exists. It also runs ahead of the analysts' revenue path.
Reverse discounted cash flow: 10% discount rate, 3% growth after year ten, starting from trailing twelve months free cash flow of $3.88B. Inputs: FMP statements, estimates and quote.
How the stock reacts to earnings
EPS beat in 10 of the last 12 reports (2024–2026); the stock still fell the next session after 5 of those beats. Average first-session move: 5.4% either way.
- +7.4%Jan ’24
- -6.0%May ’24
- +5.8%Jul ’24
- +5.9%Nov ’24
- -2.2%Feb ’25
- -2.4%May ’25
- -4.8%Aug ’25
- +4.6%Nov ’25
- -2.7%Feb ’26
- -16.4%May ’26
- +6.1%Aug ’26
- -0.2%Nov ’26
Every report, with revenue and five-session moves
| Report | EPS | Revenue | Next session | 5 sessions |
|---|---|---|---|---|
| Beat | In line | -0.2% | — | |
| Beat | In line | +6.1% | +2.6% | |
| Miss | Miss | -16.4% | -16.4% | |
| In line | In line | -2.7% | +1.1% | |
| Beat | In line | +4.6% | +5.5% | |
| Beat | In line | -4.8% | -0.4% | |
| Beat | In line | -2.4% | -4.0% | |
| Beat | Beat | -2.2% | -3.2% | |
| Beat | Beat | +5.9% | +6.8% | |
| Beat | Beat | +5.8% | +4.4% | |
| Beat | Miss | -6.0% | -6.2% | |
| Beat | Beat | +7.4% | +7.8% |
Beating the estimate has not been enough: the stock fell after 5 of the last 10 beats. The bar it has to clear is the whisper number, not the published one.
What management is saying differently
Management's own words on the Q4 FY2026 call () against Q3 FY2026 (). Analysts' questions are left out.
- New this call: “services segment”, “provider services”, “operating model”, “solutions segment” — none of them came up in Q3 FY2026.
- Getting louder: “operating income” (2 → 23 mentions), “long term” (2 → 19 mentions), “income growth” (1 → 12 mentions).
- Gone quiet: “pharmaceutical-centric strategy”, “community physician”, “care system”, “early days” — regular themes last call, absent this time.
- Tone: Cautious words such as “may”, “could” and “headwind” fell from 3.2 to 1.6 per 1,000 words, and confident words such as “record” and “strong” fell from 4.7 to 3.8.
Management sounded more assured than a quarter earlier — fewer hedging words, more of the confident kind.
Our track record on this stock
Since the score went from 80 to 86 while the share price moved +5.4% through .
| Date | Band | 3 months | 6 months | Call |
|---|---|---|---|---|
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — | |
| Strong → Exceptional | — | — | — | |
| Exceptional → Strong | — | — | — |
None of the 7 band changes we have recorded has been graded yet; we grade each band change three months after it happens.
The crowd against our signals
- Analysts: 72% of 46 rate it a buy; the average target sits +4.8% from the price of $341.25.
- Last 90 days: 9 rating actions, every one a reaffirmation.
- Our signals: Exceptional band; strongest pillar Growth Durability (93), weakest Financial Safety (58).
Here we and the crowd agree.
Price & events
Triangles mark reported quarters on the line: pointing up is above the recorded estimate, down is below, a diamond means no estimate on file. Numbers key to the dated list. Point at or tab to any week for its close.
Events behind the price
- · Earnings results · above the recorded estimate
- · Earnings results · below the recorded estimate
- · Earnings results · above the recorded estimate
- · Earnings results · above the recorded estimate
Results dates follow the earnings feed; call dates follow the transcript provider. Nearby dates do not establish that an event caused a price move.
Upcoming events
How to read these dates
Estimated dates can change.
Other perspectives
Council score for Cencora (COR): perspectives
Some lenses disagree with the MoonshotScore. Compare their readings below; each uses a different method.
5-Factor Breakdown
Legends Council
6 lenses, 6 current
AI simulations built from the named investors' published principles. Not affiliated with, endorsed by, or the opinion of these individuals. How these lenses are built
Read on: Nov 19, 2026
Munger's Mindset
Balance Sheet & Valuation
Read on: Nov 19, 2026
How to read these bars and different assessments
Council is a separate blend of available disciplines; MoonshotScore above remains the five-pillar research rating.
Bars show each model's ordered assessment on its own scale, not a probability or a comparable investment return. The adjacent words give the assessment; more filled segments indicate a stronger model reading.
One of these lenses reads this company less favourably than the MoonshotScore does: Financial health lens. Each lens is a separate scoring function over its own inputs, so a disagreement is a difference of method rather than a correction — the page's answer stays the MoonshotScore above.
The Munger lens reads the current price as fairly valued against its own estimate of value.
Readings on this page are from Nov 20, 2026, except a card that shows its own read date.
What is Cencora (COR), and what does it report?
Short answer · as of
Pharmaceutical distribution supplies most of Cencora’s revenue.
Research dated 2026-09-12.
The company sources and delivers branded, generic, injectable and specialty medicines, along with vaccines, blood products, health supplies and animal-health products; it also serves manufacturers through logistics, clinical, commercialization and analytics work.
Revenue therefore measures the value and volume of products passing through a broad distribution network, not sales of medicines developed by Cencora. That distinction explains how enormous sales can coexist with narrow gross, operating and net margins.
What do the latest results show for Cencora (COR)?
Research dated 2026-09-12.
The latest period extended the longer run of revenue growth and lifted gross profit from the preceding report. Operating profit and net income retreated from the unusually strong prior period as selling and administrative expense increased, yet each remained above the comparable earlier period.
Reported revenue and earnings also cleared market expectations in the latest release after the preceding release missed on each measure. Management separately attributed a reduced reported-growth outlook for International Healthcare Solutions to a stronger dollar, while still describing positive growth on a constant-currency basis.
Where is operating spending going?
Revenue alongside research and development, selling, general and administrative expenses, and the FMP standardized operating result.
| Period end | Revenue | R&D | SG&A | FMP standardized operating result |
|---|---|---|---|---|
| Jun 30, 2026 | Not available | Not available | Not available | Not available |
| Mar 31, 2026 | Not available | Not available | Not available | Not available |
| Dec 31, 2025 | Not available | Not available | Not available | Not available |
| Sep 30, 2025 | Not available | Not available | Not available | Not available |
How to read these figures
Amounts are in US dollars. The operating result is Financial Modeling Prep’s standardized figure, so it can differ from the operating line in the company’s filing. It is not net income or cash flow.
Did results meet expectations?
Reported earnings and revenue alongside the estimates recorded by the provider.
- Latest report · revenue
- $88.35B Nov 4, 2026
- Latest report · revenue estimate
- $87.95B Nov 4, 2026
- Latest report · revenue vs estimate
- Above estimate Nov 4, 2026
- Latest report · EPS vs estimate
- Above estimate Nov 4, 2026
| Report date | Revenue · reported | Revenue · estimate | EPS · reported | EPS · estimate |
|---|---|---|---|---|
| Nov 4, 2026 | $88.35B | $87.95B | $4.6600 | $4.5800 |
| Aug 5, 2026 | $84.75B | $84.31B | $4.4800 | $4.3500 |
| May 6, 2026 | $78.36B | $81.09B | $4.7500 | $4.8200 |
| Feb 4, 2026 | $85.93B | $86.06B | $4.0800 | $4.0500 |
How to read these figures
Dates are when results were reported, not quarter ends. Amounts are in US dollars; EPS is per share. The source does not say whether EPS is basic, diluted or adjusted, so it can differ from the EPS in the income statement.
Quarterly income statement — 4 quarters
| Period | Revenue | Net income | EPS |
|---|---|---|---|
| Jun 2025 | $80.66B | $687M | — |
| Sep 2025 | $83.73B | -$340M | -$1.75 (diluted) |
| Q1 FY2026 | $85.93B | $560M | $2.87 (diluted) |
| Q2 FY2026 | $78.36B | $1.64B | $8.40 (diluted) |
What are the financial strengths and risks for Cencora (COR)?
Short answer
Cash and short-term investments were $0.00 at the Jun 30, 2026 balance-sheet date. This figure does not establish a cash runway.
Research dated 2026-09-12.
Cencora generates substantial operating cash, but the quarterly pattern is uneven: large outflows have been followed by strong inflows, and recent operating cash comfortably exceeded capital spending. Cash has rebuilt from its recent low, though it remains below the opening level of the reported window.
The balance sheet deserves attention because debt materially exceeds cash and short-term investments, while liquidity ratios sit below full coverage of current obligations. Thin margins magnify the consequence of reimbursement pressure, customer pricing concessions, distribution cost inflation or a mix shift toward lower-spread products: a modest loss of spread can absorb a meaningful share of profit even when revenue remains high.
What should you watch next at Cencora (COR)?
Short answer · as of
The next earnings report is expected on Feb 3, 2027.
Research dated 2026-09-12.
The upcoming report should be read across several connected signals: whether revenue clears the higher consensus bar, whether gross-profit growth survives rising operating expense, and whether operating profit rebounds from the latest sequential decline. Cash conversion matters just as much because recent inflows followed a material outflow, making a smooth reading from any isolated period unreliable.
International Healthcare Solutions offers a direct test of management’s currency explanation. Compare reported growth with the stated constant-currency direction, then watch whether pharmaceutical distribution remains the main source of expansion and whether cash accumulation begins to narrow the debt gap. Recent financing and leadership filings also warrant attention for any effect on capital structure or execution responsibilities.
What the records here don't tell us
- No forward revenue or earnings estimate is on file.
Checked against the records this page reads, on the dates shown above.
How does Cencora compare with its peers?
Short answer
Cencora's score ranks 4th of 7 in the bounded comparison shown, against 6 same-model peers. These are company scores, not expected investment returns. The set lists named competitors first, then companies in the same data-provider industry classification closest in market value; that classification is the provider's, not our judgment of business similarity.
Research dated 2026-09-12.
Cencora resembles other pharmaceutical wholesalers in combining vast product throughput with slim margins, but its operating footprint reaches beyond conventional drug delivery. Specialty medicines, manufacturer commercialization services, biopharmaceutical transport, animal health and international wholesale place more of the medicine journey inside the same network.
That breadth does not change the economics of the core business: pharmaceutical distribution still supplies the overwhelming majority of revenue. The differentiator is the ability to attach specialized logistics and services to that flow, rather than ownership of a proprietary drug portfolio.
| Company | Price | Market value | Score |
|---|---|---|---|
| $46.66 Nov 19, 2026 | $2.96B | 96 5-pillar Nov 18, 2026 | |
| $1084.43 Nov 18, 2026 | $125B | 92 5-pillar Nov 18, 2026 | |
| $272.37 Nov 19, 2026 | $63.0B | 88 5-pillar Nov 18, 2026 | |
| Cencora (COR) — this page | $341.25 | $65.1B | 86 |
| $85.69 Nov 18, 2026 | $9.47B | 73 5-pillar Nov 18, 2026 | |
| $212.73 Nov 19, 2026 | $57.9B | 68 5-pillar Nov 18, 2026 | |
| $50.62 Nov 18, 2026 | $2.40B | 63 5-pillar Nov 18, 2026 |
Only 5-pillar scores are ranked together. Other models are not directly comparable. Price and score dates are shown separately; market-value dates are unavailable.
The records behind this page
Analyst targets & estimates
What analysts have on file
- Price target, low to high
- $330.00 – $400.00
- Consensus target
- $364.00
- Median target
- $350.00
Consensus record · Captured .
Measured against a quoted price of $341.25 (as of Nov 19, 2026).
Insider activity
Form 4 records via FMP · Of the newest 100 records, those within the last 180 days, newest dated Nov 12, 2026
- Transactions
- 53
- Identified insiders
- 12
- Purchases
- 3
- Sales
- 5
- Other transactions
- 45
Purchases and sales use the reported transaction category. Other transactions include awards, exercises, gifts, withholding and unclassified activity; an acquisition or disposition alone is not a purchase or sale. These records do not establish intent.
Who holds the shares?
Institutional ownership reported through 13F filings.
Tracked investors
Which of the 16 named investors we follow held COR in their latest 13F filing, and what they did against the filing before it.
| Investor | Manager | 13F quarter | Portfolio weight | Value | Last quarter |
|---|---|---|---|---|---|
| Bridgewater Associates | Founded by Ray Dalio | Q3 2026 | 0.07% | $15.13M | Added +48.0% shares |
How to read these figures
These filings arrive after the quarter ends. Names appear as the provider lists them, not as a verified ranking, and without filing dates. Related managers can appear separately, so their shares are not added together. Tracked investors: each fund's own latest 13F, so funds that have not filed the newest quarter yet show their previous one; weight is the share of the fund's reported 13F value.
What has been published about Cencora (COR)?
Common Questions About COR (Healthcare)
Research dated 2026-09-12; the full attribution is under Sources. The last 2 questions are answered from this page's own dated data, not from the research.
What does Cencora’s Pharmaceutical Distribution business actually sell?
It supplies pharmacies, hospitals, clinics and other care providers with branded, generic, injectable and specialty medicines, plus vaccines, blood products and related health supplies. Revenue primarily reflects products moving through that network rather than medicines invented by Cencora.
Why can Cencora’s revenue rise while its margins stay thin?
Medicine distribution records a large product value as revenue while retaining only a narrow spread after product and operating costs. Recent results show sales and gross profit advancing together, but the margin ratios confirm that only a small portion reaches operating profit and net income.
How does International Healthcare Solutions expose Cencora to currency movements?
That segment conducts pharmaceutical wholesale and commercialization work across international markets, so currency translation can change reported growth. Management said a stronger dollar reduced its reported-growth outlook even though the constant-currency direction remained positive.
Why is Cencora’s operating cash flow so uneven?
Cash flow swings sharply between outflows and inflows even while revenue remains comparatively steady, consistent with a high-throughput distributor carrying large working-capital movements. The recent recovery is encouraging, but the broader sequence makes cumulative cash conversion more informative than an isolated period.
What is the COR stock price today?
The last price recorded for Cencora, Inc. (COR), with its trading session and source, is listed under Price & valuation on this page. It is a provider snapshot, not a live exchange feed, so check a brokerage quote before you trade.
What is the COR price target?
The analyst consensus price target for Cencora, Inc. (COR), with its range and the date it was captured from FMP, is listed under Analyst targets & estimates on this page. Targets are analyst opinions and change often; they are not a Stock Expert AI forecast.
Research written by Codex (gpt-5.6-sol) on 2026-09-12. AI-authored analysis; source dates are listed under Sources. Editorial oversight is systemic, not page-by-page. Editorially accountable: Sedat ANAK, Founder and Editor-in-Chief.
Sources: the source register lists the 42 figures on this page — 1 from SEC filings and earnings calls, 35 from Financial Modeling Prep (FMP), 3 with no recorded source, 2 computed by us, formula shown in the register and 1 from Stock Expert AI's own score and rank. Its rows (value as shown, as-of date, tier and source link) are in the Markdown version of this page.
Publication details and research sources
- Published
- Research standards
- Methodology · Editorial policy · Corrections
- Report a number
- sedat@stockexpertai.com
Sources (as of 2026-09-12), by section of the research
ETFs that hold COR
Funds in our ETF coverage that list COR among the top 10 holdings on their fund page, largest weight first. Each weight is the fund's reported holding weight as of the date in its row.
| ETF | Weight | Holdings as of |
|---|---|---|
| SMI 3Fourteen Full-Cycle Trend ETF (FCTE) | 5.15% | |
| JMID ETF | 3.84% | |
| iShares Russell Mid-Cap Growth ETF (IWP) | 2.30% | |
| Vanguard Mid-Cap Value ETF (VOE) | 1.19% | |
| T. Rowe Price Hedged Equity ETF (THEQ) | 0.31% |
